Article

Les effets de l’ayahuasca sur le système nerveux central: étude comportementale

Phytotherapie 12/2008; 5(5):254-257. DOI: 10.1007/s10298-007-0266-y

ABSTRACT Un échantillon de la boisson ayahuasca contenant les alcaloïdes harmalol, harmol, harmane et N,N-diméthyltryptamine a été
évalué dans les tests de nage forcée et d’open-field. Dans le test de nage forcée, les doses ont diminué le temps d’immobilité
d’une manière inversement proportionnelle à la dose. Des doses de 2,5 mg/kg et de 10 mg/kg d’ayahuasca ont diminué aussi l’activité
locomotrice et l’exploration verticale dans le test d’open-field. La dose de 2,5 mg/kg a amené à une diminution de l’activité
locomotrice de 44,95% et de 62,12% pour l’exploration verticale. On peut avancer l’hypothèse d’une relation inversement proportionnelle
entre dose et effet; la dose de 2,5 mg/kg a montré une activité antidépressive.
An ayahuasca beverage sample, containing harmalol, harmol, harmane and N,N-Dimethyltryptamine alkaloids, was evaluated in
the forced swimming and open field tests. In the forced swimming test, the doses have decreased the immobility time in inverse
dose-dependant way. Doses of 2.5mg/kg and 10mg/kg of ayahuasca also decreased the locomotor activity and vertical exploration
on open field test. The 2.5mg/kg dose decreased the locomotor activity in 44.95% and the vertical exploration in 62.12%. It
is possible to suggest that doses are relationed in inverse dose-dependent way, and the 2.5mg/kg dose presented antidepressant
activity.

Download full-text

Full-text

Available from: Fabio Perazzo, Aug 20, 2015
3 Followers
 · 
332 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Harmine, harmaline, tetrahydroharmine (THH), and N,N-dimethyltryptamine (DMT) were quantitated in plasma from 15 healthy male volunteers after the ingestion of ayahuasca, a beverage that has been used for religious purposes in Brazil since pre-Columbian times. A growing awareness of the interest in this ancient shamanistic practice in modern urban cultures and the widespread popular dissemination of the inebriant effects and type and sources of the plant admixtures used to prepare the beverage have provided additional impetus for this study. The three harmala alkaloids were quantitated from protein-precipitated plasma by high-performance liquid chromatography using fluorescence detection. Recovery from blank human plasma was quantitative, and the limit of quantitation (LOQ) was below 2 ng/mL of plasma for each of the harmala alkaloids. Standard concentrations ranged from 10 to 250 ng/mL for harmine and THH and from 1.0 to 25.0 ng/mL for harmaline, respectively. Linearity was observed for harmine, harmaline, and THH within these respective ranges. The highest concentrations of harmala alkaloids in human plasma were found to be 222.3 ng/mL for harmine, 134.5 ng/mL for THH, and 9.4 ng/mL for harmaline. DMT was quantitated by gas chromatography using nitrogen-phosphorus detection after liquid-liquid extraction with diphenhydramine as an internal standard. DMT recovery was quantitative, and the limit of detection and LOQ were 0.5 and 5 ng/mL, respectively. Linearity for DMT was observed from 5 to 1000 ng/mL. The one-step extraction method for DMT and the protein precipitation method for the three harmala alkaloids afford rapid, sensitive, and quantitative analyses of these alkaloids with minimal analyte loss. The analytical methods also may be applicable to other matrices, including whole blood and urine samples and homogenized tissue specimens. These are the first reported observations of DMT and harmala alkaloids in plasma after ritual ingestion of ayahuasca.
    Journal of analytical toxicology 11/1996; 20(6):492-7. DOI:10.1093/jat/20.6.492 · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nomifensine was shown to be a potent stereotypic agent in rat. Its effect was resistant to a-methylparatyrosine pretreatment but was abolished by combined reserpine/alpha-methylparatyrosine and by haloperidol. Electrolytic lesions placed in dopamine-containing areas of the extra-pyramidal, mesolimbic and amygdaloid systems indicated an effect in all areas, but the globus pallidus and substantianigra were shown to be most important for its action. Also the effect of nomifensine was reduced by lesions of the medial and/or dorsal raphé nuclei. A circling behaviour was recorded following nomifensine administration to animals with unilateral electrolytic lesions of the substantia nigra or asymmetric lesions of the medial raphé nucleus. These effects were resistant to alpha-methylparatyrosine and inhibited by haloperidol. Nomifensine reduced the intensity of harmine-induced tremor. The M2-metabolic of nomifensine mimicked the effects of the parent compound on peripheral administration bu the onset of action was more rapid and the duration shorter. The M2-metabolite was active on intrastriatal injection to induce stereotyped/hyperactive behaviour and contralateral asymmetries. In all experimental situations nomifensine was compared with apomorphine and d-amphetamine (dopamine and L-Dopa where appropriate). Nomifensine/metabolite was shown to be a potent dopaminergic agonist with an action mainly dependent upon functioning of the extrapyramidal system and partly independent of presynaptic mechanisms.
    Psychopharmacology 02/1975; 41(2):153-64. DOI:10.1007/BF00421073 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The forced swimming test (FST) predicts the efficacy of clinically effective antidepressants. In the present study, using the FST we examined the antidepressant potential of three novel tropane analogs: 8-methyl-2beta-propanoyl-3beta-(4-(1-methylethyl)phenyl)-8-azabicy clo[3.2.1] (WF-31) and 2beta-propanoyl-3beta-(4-(1-methylethyl)phenyl)-8-azabicyclo[3.2.1 ]octane (WF-50), selective inhibitors of serotonin uptake, and 8-methyl-2beta-propanoyl-3beta-(4-(1-methylphenyl)-8-azabicyclo[3. 2.1] octane (PTT, WF-11), a selective inhibitor of dopamine uptake. Fluoxetine and GBR 12909 were used as controls for selective inhibitors of serotonin and dopamine, respectively. Drugs were administered three times in a 24-hr period between pretest and test sessions. Intraperitoneal administration of WF-31 (0.1-10.0 mg/kg), WF-50 (0.3-10.0 mg/kg) and fluoxetine (0.3-10.0 mg/kg) dose-dependently decreased immobility while increasing swimming. In contrast, WF-11 (0.3-3.0 mg/kg) dose-dependently decreased immobility and increased both swimming and climbing, whereas GBR 12909 (3.0-30.0 mg/kg) decreased immobility, increased climbing but did not affect swimming. In a separate experiment, WF-11 (1.0 mg/kg) increased locomotor activity, whereas a higher dose of WF-11 (3.0 mg/kg) and GBR-12909 (30.0 mg/kg) produced stereotypic behaviors, suggesting that the effects in the FST may have been attributable to increases in general activity. However, the effects of WF-11 on swimming in the FST indicate that WF-11 produces antidepressant-like effects in addition to motor stimulation. These results confirm previous results that behavioral patterns manifested in the FST are characteristic of specific monoamine uptake inhibitors. In addition, these results demonstrate that WF-31 and WF-50 produce behavioral patterns similar to fluoxetine in the FST without accompanying decreases in motor activity, suggesting a potential antidepressant action. Based on comparisons with fluoxetine, the data suggest WF-31 and WF-50 may be therapeutically useful as potential antidepressant medications.
    Journal of Pharmacology and Experimental Therapeutics 09/1997; 282(2):727-33. · 3.86 Impact Factor
Show more